title: A clinical comparison of budesonide nasal aerosol, terfenadine and a combined therapy of budesonide and oxymetazoline in adult patients with perennial rhinitis.
abstract: The efficacy of budesonide, terfenadine and a combination of budesonide and oxymetazoline in the treatment of perennial rhinitis was evaluated by a double blind, parallel group study. Adult patients with perennial rhinitis were randomized into three groups. Group 1 patients received budesonide nasal aerosol 400 micrograms/day for 21 days and oxymetazoline nasal drops for the first three days. Group 2 and 3 patients received budesonide 400 micrograms/day and terfenadne tablet 60 mg twice/day respectively. Nasal symptoms were assessed by the patients before and daily during the treatment period using a simple scoring system. One hundred and forty-two patients were recruited and 130 completed the study. Budesonide, but not terfenadine, significantly reduced all nasal symptoms from baseline (p less than 0.05). Terfenadine could significantly relieve the nasal blockage (p less than 0.05) more than other nasal symptoms. Budesonide with or without oxymetazoline nasal drops provided a better control of nasal symptoms than terfenadine (p less than 0.05). Budesonide with oxymetazoline for the first three days showed a faster relief of nasal blockage than budesonide alone (p less than 0.05). Mild and transient adverse effects were encountered in all three groups. It is concluded that nasal symptoms of perennial rhinitis are more adequately controlled by budesonide than by terfenadine.
authors.affiliation: Department of Surgery, University of Hong Kong.
authors.forename: S K
authors.initials: SK
authors.lastname: Lau
authors.forename: W I
authors.initials: WI
authors.lastname: Wei
authors.forename: C A
authors.initials: CA
authors.lastname: Van Hasselt
authors.forename: C L
authors.initials: CL
authors.lastname: Sham
authors.forename: J
authors.initials: J
authors.lastname: Woo
authors.forename: D
authors.initials: D
authors.lastname: Choa
authors.forename: U C
authors.initials: UC
authors.lastname: Engzell
mesh_terms: D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000368:Aged; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019819:Budesonide; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014663:Nasal Decongestants / Q000008:administration & dosage / Q000627:therapeutic use; D010109:Oxymetazoline / Q000008:administration & dosage*; D011282:Pregnenediones / Q000008:administration & dosage*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D016593:Terfenadine
chemical_list: D000336:Aerosols; D001559:Benzhydryl Compounds; D001993:Bronchodilator Agents; D006634:Histamine H1 Antagonists; D014663:Nasal Decongestants; D011282:Pregnenediones; D019819:Budesonide; D016593:Terfenadine; D010109:Oxymetazoline